Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

68Ga PentixaFor - PentixaPharm

Next Previous
X
Search
Drug Profile

68Ga PentixaFor - PentixaPharm

Alternative Names: 68Ga-PTF; 68Ga-PentixaFor; [68Ga]Ga-PentixaFor; [68Ga]Ga-PentixaFor PET/CT; [68Ga]Ga-PTF; [68Ga]Pentixafor; CXCR4-PET

Latest Information Update: 28 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Scintomics; University of Munich
  • Developer Peking Union Medical College Hospital; PentixaPharm
  • Class Antineoplastics; Cyclic peptides; Imaging agents; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers; Tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Marginal zone B-cell lymphoma
  • Phase II/III Adrenal cancer
  • Phase II Lymphoma; Multiple myeloma; Myocarditis
  • Phase 0 Blood dyscrasias; Non-Hodgkin's lymphoma; Smoldering multiple myeloma; Thymoma
  • Clinical Phase Unknown Giant cell arteritis; Myocardial infarction
  • No development reported Hyperaldosteronism; Lymphoproliferative disorders; Neuroendocrine tumours

Most Recent Events

  • 28 Jul 2024 No recent reports of development identified for clinical-Phase-Unknown development in Hyperaldosteronism(Diagnosis) in China (IV, Injection)
  • 28 Jul 2024 No recent reports of development identified for phase-0 development in Lymphoma(Diagnosis) in China (IV, Injection)
  • 28 Jul 2024 No recent reports of development identified for phase-0 development in Lymphoproliferative disorders(Diagnosis) in China (IV, Injection)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top